Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Home

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Diabetes Technology & Therapeutics|June 15, 2011
Hypoglycemia rates with basal insulin analogsStuart Little, James Shaw, Philip Home
Expert Review of Endocrinology & Metabolism|July 31, 2018
IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current statusJens Sandahl Christiansen, Philip Home, Ajay Kumar
Diabetes Technology & Therapeutics|March 20, 2015
An Overview of Current Regulatory Requirements for Approval of Biosimilar InsulinsLutz Heinemann, Hootan Khatami, Ross McKinnon, et al.
Health & Place|April 26, 2026
Spatial dynamics of biodiversity and cycling behaviour: A geographical analysis using crowdsourced data from Strava metroPhilip Home, Sabrina L Li, Doreen S Boyd
Diabetes Research and Clinical Practice|June 27, 2018
2020 vision - An overview of prospects for diabetes management and prevention in the next decadeChih-Yuan Wang, David L Neil, Philip Home
Annals of the New York Academy of Sciences|December 8, 2006
Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up studyLatika Sibal, Huong Nai Law, Janice Gebbie, et al.
Diabetes Research and Clinical Practice|October 12, 2014
An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetesAsrul Akmal Shafie, Vishal Gupta, Ranya Baabbad, et al.
Journal of Diabetes Science and Technology|July 12, 2022
Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical TrialsLutz Heinemann, Melanie Davies, Philip Home, et al.
Journal of Medical Economics|November 20, 2014
An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetesPhilip Home, Sei Hyun Baik, Guillermo González Gálvez, et al.
Diabetes Care|May 30, 2006
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetesKjeld Hermansen, Melanie Davies, Taudeusz Derezinski, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Diabetes Technology & Therapeutics|June 15, 2011
Hypoglycemia rates with basal insulin analogsStuart Little, James Shaw, Philip Home
Expert Review of Endocrinology & Metabolism|July 31, 2018
IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current statusJens Sandahl Christiansen, Philip Home, Ajay Kumar
Diabetes Technology & Therapeutics|March 20, 2015
An Overview of Current Regulatory Requirements for Approval of Biosimilar InsulinsLutz Heinemann, Hootan Khatami, Ross McKinnon, et al.
Health & Place|April 26, 2026
Spatial dynamics of biodiversity and cycling behaviour: A geographical analysis using crowdsourced data from Strava metroPhilip Home, Sabrina L Li, Doreen S Boyd
Diabetes Research and Clinical Practice|June 27, 2018
2020 vision - An overview of prospects for diabetes management and prevention in the next decadeChih-Yuan Wang, David L Neil, Philip Home
Annals of the New York Academy of Sciences|December 8, 2006
Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up studyLatika Sibal, Huong Nai Law, Janice Gebbie, et al.
Diabetes Research and Clinical Practice|October 12, 2014
An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetesAsrul Akmal Shafie, Vishal Gupta, Ranya Baabbad, et al.
Journal of Diabetes Science and Technology|July 12, 2022
Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical TrialsLutz Heinemann, Melanie Davies, Philip Home, et al.
Journal of Medical Economics|November 20, 2014
An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetesPhilip Home, Sei Hyun Baik, Guillermo González Gálvez, et al.
Diabetes Care|May 30, 2006
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetesKjeld Hermansen, Melanie Davies, Taudeusz Derezinski, et al.
Pageof 5